Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Earnings for Ocular Therapeutix, Inc. (OCUL)
Earnings in 2023 (TTM): $-80,736,000
According to Ocular Therapeutix, Inc.'s latest financial reports the company's current earnings (TTM) are $-80,736,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ocular Therapeutix, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-80,736,000 | $-80,736,000 |
| 2022 | $-71,038,000 | $-63,422,000 |
| 2021 | $-6,553,000 | $-10,804,000 |
| 2020 | $-155,636,000 | $-159,631,000 |
| 2019 | $-86,372,000 | $-89,935,000 |
| 2018 | $-59,978,000 | $-57,692,000 |
| 2017 | $-63,386,000 | $-63,386,000 |
| 2016 | $-44,703,000 | $-44,703,000 |
| 2015 | $-39,748,000 | $-39,748,000 |
| 2014 | $-28,648,000 | $-28,648,000 |
| 2013 | $-13,317,000 | $-13,317,000 |
| 2012 | $-14,093,000 | $-14,093,000 |